Source:http://linkedlifedata.com/resource/pubmed/id/12029639
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2002-5-24
|
pubmed:abstractText |
During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti-HBe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous seroconversion are still scarce. Excluding patients with other virus(es) concurrent infection, 283 patients with chronic HBV infection were followed up for at least 1 year after spontaneous HBeAg seroconversion to anti-HBe. Follow-up studies included clinical, biochemical, and virologic evaluation and hepatocellular carcinoma (HCC) screening with ultrasonography and alpha-fetoprotein assay. During a median follow-up period of 8.6 years (range, 1 to 18.4 years) after HBeAg seroconversion in 283 patients, 189 (66.8%) showed sustained remission, whereas the remaining 94 (33.2%) experienced alanine aminotransferase (ALT) elevation over twice the upper limit of normal: 12 (4.2%) associated with HBeAg reversion, 68 (24%) with detectable serum HBV DNA but HBeAg negative, and 14 (4.9%) of undetermined causes. Of the 269 patients without evidence of cirrhosis at the time of HBeAg seroconversion, 21 (7.8%) developed cirrhosis with a cumulative incidence and relative risk significantly higher in patients developing active hepatitis than in patients with sustained remission (P <.05). HCC developed in 6 (2.2%) of the 283 patients, also with a significantly higher cumulative incidence in patients developing active hepatitis after HBeAg seroconversion (P <.005). In conclusion, the results suggest that spontaneous HBeAg seroconversion confers favorable long-term outcomes. However, active hepatitis still may develop and lead to cirrhosis and HCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1522-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12029639-Adolescent,
pubmed-meshheading:12029639-Adult,
pubmed-meshheading:12029639-Carcinoma, Hepatocellular,
pubmed-meshheading:12029639-Female,
pubmed-meshheading:12029639-Follow-Up Studies,
pubmed-meshheading:12029639-Hepatitis B, Chronic,
pubmed-meshheading:12029639-Hepatitis B Antibodies,
pubmed-meshheading:12029639-Hepatitis B e Antigens,
pubmed-meshheading:12029639-Humans,
pubmed-meshheading:12029639-Incidence,
pubmed-meshheading:12029639-Liver Cirrhosis,
pubmed-meshheading:12029639-Liver Neoplasms,
pubmed-meshheading:12029639-Male,
pubmed-meshheading:12029639-Middle Aged,
pubmed-meshheading:12029639-Remission, Spontaneous,
pubmed-meshheading:12029639-Risk Factors
|
pubmed:year |
2002
|
pubmed:articleTitle |
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
|
pubmed:affiliation |
Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|